Caen Cedex 5

• Phase 1 Study of IMC-P115C in Advanced PRAME Positive Cancers Recruiting
  2023-509767-25-00 1 2024-11-07 Advanced PRAME Positive Cancers
• Immunotherapy and chemotherapy treatment or no treatment guided by the level of tumour-infiltrating cells in resected early-stage triple-neg … Recruiting
  2023-504620-26-00 4 2024-11-04 Triple negative breast cancer
• A prospective, multicentre, open-label, randomized, Phase II study of Pembrolizumab in combination with neo-adjuvant EC-Paclitaxel regimen i … Recruiting
  2024-514899-41-00 4 2024-10-31 Breast cancer
• An international multicentric randomized phase II evaluating dostarlimab in combination with niraparib versus niraparib alone compared to ch … Recruiting
  2024-516782-36-00 4 2024-10-15 metastatic or recurrent endometrial or ovarian carcinosarcoma
• Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag … Recruiting
  2023-507482-26-00 5 2024-10-04 Castrate-resistant prostate cancer with oligometastases on functional
• OPEN-LABEL PHASE II EFFICACY STUDY OF REPOTRECTINIB IN FRAIL (PS ≥2) AND /OR ELDERLYPATIENTS WITH ROS1-REARRANGED ADVANCED NSCLC Recruiting
  2023-509073-23-00 4 2024-10-01 Stage III/IV non-small-cell lung cancer (NSCLC) harboring an ROS1 gene
• HARMONi-3 Recruiting
  2024-513087-26-00 5 2024-09-10 Metastatic Non-small Cell Lung Cancer
• Study evaluating whether giving 177Lu-PSMA-617 to men having a spreading prostate cancer which does not respond well to the current standard … Recruiting
  2022-502408-57-00 5 2024-09-04 Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients hav
• PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting
  2024-515297-27-00 5 2024-08-14 colon carcinoma
• SALVOVAR trial: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVa … Recruiting
  2023-508260-30-01 5 2024-07-30 Patients with poor prognostic OVARian cancers based on the tumor prima
• Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizu … Recruiting
  2024-515788-73-00 4 2024-07-30 MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND A HIGH IM
• Immunotherapy with dostarlimab for locally advanced or metastatic cancer (non-colorectal/non-endometrial) with tumor dMMR/MSI Recruiting
  2023-505298-34-00 4 2024-07-18 Patients with dMMR/MSI (non-colorectal/non-endometrial) locally advanc
• Study of RMC-6291 and RMC-6236 With Other Anti-Cancer Agents in Patients With RAS G12C-Mutated NSCLC - Subprotocol A Recruiting
  2023-509571-16-00 3 2024-07-17 Lung Cancer
• A study of RMC-6236 in combination with pembrolizumab in participants with nonsmall cell lung cancer with certain mutations -Subprotocol B Recruiting
  2023-509572-42-00 3 2024-07-17 Lung Cancer
• Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer Recruiting
  2023-504962-52-00 5 2024-07-10 Triple negative breast cancer.
• Personalized medicine for advanced biliary cancer patients Recruiting
  2023-508100-38-00 5 2024-06-24 Advanced Biliary Cancer (ABC)
• A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Can … Recruiting
  2023-507914-28-00 10 2024-06-19 Platinum-resistant, high-grade serous ovarian cancer (OVC),high-grade
• FIRST-NEC - A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab (MEDI 4736) with etoposide and … Recruiting
  2023-506590-35-00 4 2024-06-13 Large-Cell NeuroEndocrine Carcinoma of the lung
• A Phase 3 study of Dostarlimab as Sequential Therapy after Chemoradiation compared to placebo in adult participants with Locally Advanced Un … Recruiting
  2023-508613-17-00 5 2024-05-29 Neoplasms, Head and Neck
• EstroTEP and circulating biomarkers for ER-positive HER2-negative metastatic breast cancer patients Recruiting
  2023-506282-66-00 5 2024-05-27 Women with ER+ HER2- metastatic breast cancer who progressed on first
• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CD … Recruiting
  2023-506888-34-00 1 2024-05-22 Advanced or metastatic solid tumors including hormone receptor positiv
• Gut microbiome intervention with EXL01 in combination with nivolumab and FOLFOX as first-line treatment for patients with PD-L1 CPS ≥5 metas … Recruiting
  2023-506753-38-00 4 2024-04-16 metastatic gastric adenocarcinoma
• CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting
  2023-503317-29-00 5 2024-04-12 Metastatic renal cell carcinoma (mRCC)
• STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C … Recruiting
  2023-505871-63-00 5 2024-04-08 ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in

Showing 97–120 of 283 trials